425: Profusa and NorthView Acquisition Corp. Announce Potential Business Combination to Advance Real-Time Healthcare Technology

Profusa, a bio-engineered sensor company, is seeking to go public through a business combination with NorthView Acquisition Corp. to further develop and commercialize its real-time body chemistry monitoring technology.

Summary

• Profusa, Inc., a company focused on developing bio-engineered sensors for real-time monitoring of body chemistry, is seeking a business combination with NorthView Acquisition Corp. (NVAC).
• Profusa has invested nearly $100 million over 10 years in developing its technology.
• The company's key platforms include tissue oxygen monitoring, continuous glucose monitoring (CGM), and data management.
• Profusa's Lumee™ Oxygen product is already CE-marked and approved in the EU for commercial launch in 2023.
• Clinical trial data for the CGM product is compelling, and the company is seeking EU and US approvals.
• A joint venture with Tasly Pharma provides access to Asian markets and a royalty stream.
• Profusa anticipates needing $10 million in cash to reach key milestones over the next 24 months.
• The company projects revenue growth from 2022E to 2025E.
• The pro forma equity value is estimated at $275.4 million to $286.1 million, depending on redemption scenarios.
• The company's management team has experience in life sciences, diagnostics, and medical device technologies.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting the potential of Profusa's technology and its market opportunities. However, it also acknowledges the risks and challenges associated with the business combination and the company's future performance.

Positives

• Lumee™ Oxygen product is already approved in the EU.
• Compelling clinical data supports the CGM product.
• The Tasly Pharma joint venture provides access to a large Asian market.
• The company expects low COGS and distribution costs, leading to high contribution margins.
• The company believes it has sufficient cash for the next 24 months to achieve important milestones.
• The company's technology has the potential to disrupt the CGM market by offering longer sensor life and lower costs.
• The company's technology has received substantial support from DARPA and NIH.
• The company's technology has AI integration for coaching and reporting.

Negatives

• Profusa has a history of significant losses and expects this to continue.
• The company is dependent on third-party manufacturers and suppliers.
• The company may not be successful in entering into collaborations or strategic alliances.
• The company faces substantial competition in the market.
• The company may face product liability claims.
• The company may become involved in lawsuits to protect its intellectual property.
• The company's independent registered public accounting firms report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern.

Risks

• Profusa may not be able to achieve or sustain profitability.
• The company may experience delays in advancing its product candidates through clinical development and obtaining regulatory approval.
• Third-party payors may not provide adequate coverage and reimbursement for Profusa's products.
• Profusa may not be successful in commercializing its product candidates.
• The company may fail to retain its key executives or recruit and hire new employees.
• NorthView may not be able to complete its business combination within the prescribed time frame.
• NorthView may be unable to obtain additional financing to complete its business combination.
• NorthView may be required to take write-downs or write-offs, restructuring and impairment or other charges.
• NorthView may issue notes or other debt securities, or otherwise incur substantial debt, to complete its business combination.
• NorthView's executive officers and directors allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs.
• NorthView's initial stockholders, including our sponsor, executive officers and directors, will lose their entire investment in us and their right to be reimbursed for their out of pocket expenses if a business combination is not completed, a conflict of interest may have existed in determining whether the business combination is appropriate.
• NorthView's stockholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares.
• NorthView's rights and warrants may have an adverse effect on the market price of our common stock and make it more difficult to effectuate our business combination.
• NorthView's is a newly formed company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.
• NorthView's compliance obligations under the Sarbanes Oxley Act may make it more difficult for us to effectuate our business combination, require substantial financial and management resources, and increase the time and costs of completing an acquisition.

Future Outlook

Profusa anticipates several milestones in 2024-2026, including publishing human validation data, initiating pivotal studies, submitting for regulatory approvals, and commercializing its glucose and oxygen monitoring products in the EU and US.

Management Comments

• Ben Hwang, Chairman and CEO, highlights the transformative impact of science and technology on the world.
• Bill McMillan, Co-founder, CSO & Head of Research, built the company road map, enlisted top talent & secured seed funding.

Industry Context

The announcement highlights the growing market for continuous glucose monitoring and tissue oxygen monitoring, driven by the increasing prevalence of diabetes, chronic wounds, and peripheral artery disease. Profusa aims to disrupt the CGM market with its longer-lasting, lower-cost sensor technology.

Comparison to Industry Standards

• The document compares Profusa's CGM solution to existing products from Dexcom, Medtronic, Abbott, and Senseonics.
• Profusa's CGM solution boasts >270 days functionality, overcoming foreign body response, while current CGM solutions require sensor replacement every 10-14 days.
• Profusa's CGM solution has a high margin, low cost: ($900/year at >80% GM potential), while current CGM solutions cost up to $4,500 annually.

Stakeholder Impact

• Shareholders: Potential for value creation through the business combination and future growth of Profusa.
• Employees: Opportunity to work for a growing company with innovative technology.
• Customers: Access to advanced real-time monitoring solutions for glucose and oxygen levels.
• Patients: Improved healthcare outcomes through better monitoring and management of chronic conditions.

Next Steps

• NorthView and Profusa will prepare a registration statement on Form S-4 to be filed with the SEC.
• NorthView will mail a definitive proxy statement to its stockholders to vote on the potential transaction.
• Profusa will continue to develop and commercialize its Lumee™ Glucose and Oxygen products.
• Profusa will pursue regulatory approvals in the EU and US.
• Profusa will work with Tasly Pharma to expand its presence in the Asian market.

Key Dates